We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Up 7.5% Since Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Cardinal Health (CAH - Free Report) . Shares have added about 7.5% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is CAH due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
However, excluding 20 cents benefit from the legislated tax reform, adjusted earnings came in at $1.31. Meanwhile. adjusted earnings in the year-ago quarter was 1.34 per share.
Revenues increased 6.1% on a year-over-year basis to almost $35.19 billion and beat the Zacks Consensus Estimate of $34.69 billion.
Segmental Analysis
Pharmaceutical Segment
Pharmaceutical revenues soared 4.7% to $31.15 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and also gained a huge number of Pharmaceutical Distribution customers.
However, the segment witnessed a 4% drop in profits to $514 million, thanks to generic pharmaceutical pricing and the company's recent investments in its Pharmaceutical IT platform and lackluster generics program performance. However, solid performance by the Specialty Solutions business has partially offset the negative effect in the segment.
Medical Segment
Revenues at the segment increased a whopping 18.6% to $4.04 billion primarily on higher contributions from new and existing customers.
Medical segment profits increased 38% to $220 million, courtesy of higher contributions from new and existing customers and acquisition of the Patient Recovery business.
Share-Repurchase Program
Board of directors at Cardinal Health approved a new authorization to repurchase up to $1 billion of the company’s common shares, which will expire on Dec. 31, 2020.
With the latest authorization, Cardinal Health is now authorized to repurchase up to $1.3 billion of its common shares.
Margins
As a percentage of revenues, gross margin contracted 50 basis points (bps) to 5.3% of net revenues. However, gross profit in the quarter was $1.86 billion, up 16% year over year.
Distribution, selling, general and administrative (SG&A) expenses increased 24% on a year-over-year basis to $1313 billion in the reported quarter.
Guidance
Taking into consideration 40 cents per share of benefit from the lower federal rate due to U.S. tax reform, Cardinal Health raised its fiscal 2018 outlook. The company expects adjusted earnings per share from continuing operations in the range of $5.25-$5.50 per share, higher from the previously guided range of $4.85-$5.10 per share.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There have been four revisions higher for the current quarter compared to five lower.
At this time, CAH has a subpar Growth Score of D, however its Momentum is doing a lot better with an A. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and momentum investors.
Outlook
Estimates have been trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, CAH has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Up 7.5% Since Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Cardinal Health (CAH - Free Report) . Shares have added about 7.5% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is CAH due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Recent Earnings
However, excluding 20 cents benefit from the legislated tax reform, adjusted earnings came in at $1.31. Meanwhile. adjusted earnings in the year-ago quarter was 1.34 per share.
Revenues increased 6.1% on a year-over-year basis to almost $35.19 billion and beat the Zacks Consensus Estimate of $34.69 billion.
Segmental Analysis
Pharmaceutical Segment
Pharmaceutical revenues soared 4.7% to $31.15 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and also gained a huge number of Pharmaceutical Distribution customers.
However, the segment witnessed a 4% drop in profits to $514 million, thanks to generic pharmaceutical pricing and the company's recent investments in its Pharmaceutical IT platform and lackluster generics program performance. However, solid performance by the Specialty Solutions business has partially offset the negative effect in the segment.
Medical Segment
Revenues at the segment increased a whopping 18.6% to $4.04 billion primarily on higher contributions from new and existing customers.
Medical segment profits increased 38% to $220 million, courtesy of higher contributions from new and existing customers and acquisition of the Patient Recovery business.
Share-Repurchase Program
Board of directors at Cardinal Health approved a new authorization to repurchase up to $1 billion of the company’s common shares, which will expire on Dec. 31, 2020.
With the latest authorization, Cardinal Health is now authorized to repurchase up to $1.3 billion of its common shares.
Margins
As a percentage of revenues, gross margin contracted 50 basis points (bps) to 5.3% of net revenues. However, gross profit in the quarter was $1.86 billion, up 16% year over year.
Distribution, selling, general and administrative (SG&A) expenses increased 24% on a year-over-year basis to $1313 billion in the reported quarter.
Guidance
Taking into consideration 40 cents per share of benefit from the lower federal rate due to U.S. tax reform, Cardinal Health raised its fiscal 2018 outlook. The company expects adjusted earnings per share from continuing operations in the range of $5.25-$5.50 per share, higher from the previously guided range of $4.85-$5.10 per share.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There have been four revisions higher for the current quarter compared to five lower.
Cardinal Health Price and Consensus
Cardinal Health Price and Consensus | Cardinal Health Quote
VGM Scores
At this time, CAH has a subpar Growth Score of D, however its Momentum is doing a lot better with an A. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value and momentum investors.
Outlook
Estimates have been trending downward for the stock and the magnitude of these revisions indicates a downward shift. Notably, CAH has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.